Long-term treatment with antipsychotic medications alters the regional density of several of the neurotransmitter receptors that mediate cocaine toxicity. However, the effect of either up-or down-regulation of the neurotransmitter receptors on cocaine toxicity is unknown. In this study, we determined if subacute administration of the atypical antipsychotic ziprasidone altered the toxic effects of cocaine in mice. Ziprasidone (4 mg/kg) or placebo was administered to the first two groups of CF-1 mice for 10 days and, then on day 10, an estimated LD50 dose of cocaine (102 mg/kg) was given to these mice. In a third group, in order to produce a ziprasidone withdrawal state, we administered ziprasidone for 10 days, followed by no treatment for 2 days before cocaine administration. There was no significant difference among the three groups in overall survival: 63% in the treatment group, 60% in the withdrawal group, and 80% in the placebo group. Survival time was significantly shorter for the withdrawal group than for the control group. Our study may have been limited by lower than expected serum ziprasidone concentrations and lower than expected lethality from cocaine. However, our findings suggest that administration of an atypical antipsychotic for 10 days may increase the toxic effects of cocaine.
Introduction
Long-term administration of antipsychotic medications alters the regional density of dopamine, glutamate, and serotonin receptors in the brain. [1] [2] [3] [4] [5] These changes, in particular up-regulation of dopamine receptors, have been suggested as the basis for some of the adverse effects that occur with longterm antipsychotic therapy. 4 In addition to causing adverse effects, increased receptor density could increase the effects of other drugs, such as cocaine, that act through the affected neurotransmitter systems. Increased sensitivity to cocaine could result in a previously "safe" dose of cocaine producing life-threatening effects such as seizures or even death. As many patients taking antipsychotic medications also use cocaine, 6 even a modest increase in susceptibility could be a major public health concern.
The purpose of this study was to determine if administration of ziprasidone, an atypical antipsychotic for 10 days, increases the lethality of cocaine poisoning in mice. We selected an atypical antipsy-chotic because these drugs are commonly used to treat schizophrenia. We modeled two clinical scenarios: 1) cocaine use by subjects currently taking their antipsychotic medication (ongoing treatment group) and 2) cocaine use by subjects who had recently stopped taking their antipsychotic medication (withdrawal group). We hypothesized that the toxicity from acute cocaine poisoning would be higher for both the ongoing treatment and withdrawal groups, compared with control animals administered saline.
Materials and methods
We obtained male CF-1 mice (26-35 g initial weight, 29-41 g final weight) from Charles River Laboratories and allowed a minimum 7-day acclimation period before the experiments. The mice were housed in Plexiglas cages (2-5 per cage) on a 12-h light-dark cycle with free access to standard rodent food and water. We used computer generated random numbers to assign the mice to one of the three experimental groups: saline control (n = 40 mice), ongoing ziprasidone treatment (n = 40 mice), and ziprasidone withdrawal (n = 45 mice). Our local Institutional Animal Care and Use Committee (IACUC) approved all animal procedures, and we followed all NIH guidelines regarding animal welfare.
We prepared ziprasidone mesylate (Pfizer Pharmaceuticals, New York) in saline and administered it at a dose of 0.13 mg in 0.1 mL (4 mg/kg for a 33 g mouse) via subcutaneous (SC) injection. This dose approximates the therapeutic human dose based on a body surface area comparison. Control animals received 0.1 mL of normal saline. The control and ongoing treatment groups received once-daily injection for 10 days before cocaine administration. The final injection was administered 4 h before cocaine administration. The withdrawal group received daily injections for 10 days and then no injections for a 2-day washout period before cocaine administration. We selected 2 days for the withdrawal period because this would allow clearance of all drug from the brain without allowing enough time for any up-regulated receptors to return to normal levels. 7 During this withdrawal period, we handled the mice daily to keep them acclimated to handling.
In preliminary dose-response experiments, we determined that 102 mg/kg by i.p. injection was the apparent LD50 for cocaine in the CF-1 mice. We obtained cocaine HCl from Sigma Chemicals (St Louis, Missouri, USA) and dissolved it in normal saline to produce a solution containing 6.5 mg/mL of cocaine HCl. We weighed each mouse immediately before administering 0.41-0.57 mL of the cocaine solution.
Following cocaine injection, the mice were returned (in groups of 5) to a transparent glass or Plexiglas cage for 60 min of continuous observation. The primary endpoint was "apparent survival" at 60-min post cocaine administration. This endpoint was selected because all animals that survived for 60 min recovered completely in previous experiments. An observer blinded to treatment group recorded the times of seizure activity (tonic-clonic activity, straub tail, loss of righting reflex, uncontrollable running, popcorn jumping) and "apparent lethality" as defined in the next paragraph.
As per our local IACUC guidelines, we did not use death as an endpoint. Instead, we used "apparent lethality", defined as the toxic effects that occur in an animal that are usually followed by death unless the animal receives treatment. On the basis of our previous work, animals that developed irregular respirations for more than 30 s, apnea, or had seizures longer than 5 min were not likely to survive. Therefore, we euthanized animals exhibiting these effects by sodium pentothal injection (150 mg/kg i.p.) before death occurred and counted them as non-survivors. This allowed us to measure the effects of ziprasidone therapy while minimizing the distress of the experimental animals. However, occasionally animals would die from cocaine toxicity before they could be euthanized. These animals were also counted as non-survivors.
We attempted to measure serum ziprasidone levels in two mice that had received only the 10day ziprasidone treatment. The samples were obtained 4 h after the last dose and analyzed by a commercial laboratory using liquid chromatography and mass spectrometry (National Medical Services, Willow Grove, Pennsylvania, USA).
Data analysis
We performed two comparisons: controls versus the ongoing treatment group and control versus the withdrawal group. Our primary outcome was the proportion of animals surviving at 60 min and our secondary outcomes were number of animals with seizures, time interval to seizure, and time interval to apparent lethality. We calculated the 95% confidence intervals for the difference in proportions between each group. We compared the times to seizure and to apparent lethality between the two groups using a chi-square analysis of the Logrank Trend. These analyses were performed using Prism software (GraphPad Software, San Diego, California, USA). A two-sided P-value of 0.05 was considered significant for all analyses. Pre-experiment power calculations determined that a sample size of 40 animals per group would have 80% power to detect a 30% increase in lethality, assuming 50% lethality in the control group.
Results
Although we did not formally measure the behavioral effects of ziprasidone (4 mg/kg) injection, we did note some qualitative difference between the treatment groups. Placebo-treated mice appeared moderately excited immediately post-saline injection, followed by rapid resumption of normal activity. On the contrary, ziprasidone-treated mice displayed a brief period of post-handling excitation followed by marked sedation (huddling, sleeping, minimal movement) within 15 min of ziprasidone injection. The animals returned to normal activity within 4 h of treatment. The mice developed some tolerance to ziprasidone over the course of the 10day study, and were less sedated after the first few days of treatment. The mean (SD) weights of animals just before cocaine were 35.1 (2.0), 33.4 (2.4), and 34.0 (2.6) gm for the control, ongoing treatment, and withdrawal groups, respectively.
Injection of the mice with an expected LD50 dose of cocaine caused increased locomotor activity in all mice. There were no qualitative differences in activity among the three groups. The proportions of mice in the control, ongoing ziprasidone treatment, and ziprasidone withdrawal groups that experienced cocaine-induced seizures were 72%, 90%, and 84%, respectively. These percentages were not significantly different. Nor were statistical differences observed in seizure-free survival time between the control and ongoing treatment groups (χ 2 = 3.8, P = 0.05) or between the control and withdrawal groups (χ 2 = 2.4, P = 0.12; Figure 1) .
The survival times for all groups are shown in Figure 2 . Animals in the ongoing ziprasidone treatment group had a survival rate of 63% compared with the control group rate of 80% (95% confidence interval of the difference from control = −2 to 35%). The ziprasidone treatment withdrawal group had a survival rate of 60% (95% confidence interval of the difference from control = 0 to 40%). Thus, there was a trend for both ziprasidone treatment groups to have a higher mortality compared with control. The survival time for the ongoing treatment group following cocaine administration was not significantly different from that of the control group (χ 2 = 2.8, P = 0.09), whereas the survival time of the withdrawal group was significantly shorter than that of the control group (χ 2 = 4.22, P = 0.04).
Blood was drawn from two mice treated using the ongoing treatment regime at 4 h post injection on the final day. However, the levels of ziprasidone were below the lower assay detection limit of 4 ng/mL.
Discussion
We found that withdrawal from 10 days of ziprasidone administration shorted the survival of cocaine-poisoned mice. A similar, but smaller, effect was detected in the group that was still receiving ziprasidone. The shortened survival time in the withdrawal group supports the hypothesis that administration of the atypical antipsychotic ziprasidone for 10 days followed by a 2-day withdrawal period increases the toxicity of cocaine. Although we found an absolute doubling of mortality in the withdrawal group, the lower limit of the 95% confidence interval for the difference between the placebo and withdrawal group was zero; hence, we cannot exclude that mortality was equal in the two groups. We found similar but slightly smaller effects in the ongoing ziprasidone treatment group. We also found similar but non-statistically significant effects on the proportion of animals with seizures and the time to seizure onset.
Our findings are in contrast with studies evaluating acute administration of antipsychotics for treatment of cocaine poisoning. Studies have shown that acute treatment with haloperidol 8, 9 and ziprasidone 10 attenuates cocaine toxicity. One explanation of these contrasting findings would be that acute ziprasidone administration antagonizes the receptors responsible for producing the effects observed during acute toxicity, whereas long-term administration of ziprasidone causes an adaptive response (such as up-regulation of receptors that ziprasidone antagonizes), thereby increasing the sensitivity of animals to acute cocaine toxicity. Previous studies have shown that long-term treatment with antipsychotic medications alters the density of brain neurotransmitter receptors relevant to cocaine toxicity, including dopamine, glutamate, and serotonin receptors, 1-5 so there is support for this hypothesis. Our study was not designed to investigate these mechanisms, but we are planning additional studies to evaluate these hypothesis. However, our study does suggest that patients treated with antipsychotic Figure 1 Time to seizure curves for placebo, ongoing treatment, and withdrawal groups. There were no statistical differences between groups.
Figure 2
Survival curves for placebo, ongoing treatment, and withdrawal groups. Survival time was significantly longer for placebo animals than for withdrawal animals.
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medications may have increased susceptibility to cocaine poisoning.
There are several reasons why our model may have limited our ability to detect an effect of subacute ziprasidone treatment and withdrawal on mortality. First, despite using a dose scaled to the usual human daily dose (using body surface area), we did not detect therapeutic serum ziprasidone levels at 4 h. The therapeutic level is reported to be 40-130 ng/mL. 11 Although we only measured these levels in two animals, we expect that all ziprasidone-treated animals had drug levels well below therapeutic throughout their treatment, and likely also had decreased brain receptor occupancy compared with humans taking therapeutic doses of ziprasidone. This might have reduced any receptor regulation that would have occurred in response to receptor occupancy. A higher dose or a continued release of drug, rather than intermittent injections, would promote consistent receptor occupancy, thus increasing the adaptive processes likely responsible for the effects observed here. A controlled release of medication would also produce lower peak serum levels than intermittent injections, and may better reflect the levels observed with oral dosing.
Our power to detect a difference in mortality was also limited by a lower than expected mortality in the placebo group. We identified this dose of cocaine as an LD50 in a previous experiment in this mouse strain, and have successfully used it several times to produce mortality between 50% and 70%. 10, 12 We believe that the lower mortality in the placebo group observed in this study is because the animals were handled daily during the experiments. Unpredictable stress increases the behavioral effects of cocaine, and this may translate into increased toxic effects. 13 By repeatedly handling the mice, we were making the stress predicable, which would decrease the augmentation that would be caused during a one-time handling and injection. Nonetheless, the relative risk of mortality for the ongoing treatment group was twice that of the control group. In addition, the lower limit of the confidence intervals of the difference in survival was 0% between the control and the withdrawal group and a 2% increase for the control and ongoing treatment group. The consistent directions of these observed effects suggest that administration of ziprasidone for 10 days increases the susceptibility of mice to cocaine toxicity, and that our relatively small sample prevented us from identifying the difference as statistically significant.
Although the main outcome in this study was negative, we believe that the secondary outcomes and the trends in the main outcome are promising enough to warrant future studies. Chronic administration of antipsychotic medications alters the regional density of several neurotransmitter receptors in the central nervous system, including those for dopaminergic, serotonergic, cholinergic, and glutamatergic neurotransmitter systems that contribute to the acute effects of cocaine. 14, 15 Ziprasidone binds with subnanomolar affinity to serotonin 5-HT2 receptors and with nanomolar affinity to dopamine D2 receptors. 16 Long-term treatment with other atypical antipsychotics has been shown to upregulate these and other receptors. [1] [2] [3] [4] [5] 7 Ziprasidone also binds to the norepinephrine transporter, 17 although there is little evidence that the norepinephrine transporter is involved in cocaine toxicity. 18 It is also possible that ziprasidone may alter the metabolism or distribution of cocaine.
Other studies have suggested that long-term treatment with antipsychotic medication alters the behavioral response to cocaine. Mice treated with haloperidol have increased locomotor response following cocaine administration. 19, 20 A similar effect has been reported in monkeys, 21 suggesting that increased sensitivity is not a species-specific effect. We are currently planning studies with a larger sample size and a continuous infusion of antipsychotic medication to maximize our chance of detecting a difference between these groups.
